The second-most-advanced drug Sirna Therapeutics had in clinical development at the time of MRK’s 2006 buyout also appears to be dead. It was called Sirna-034 and was a dual siRNA for HCV.
Based on the Reuters story cited in #msg-34101883, MRK seems to be very happy with the Sirna deal despite the demise of essentially all of the clinical programs that were active at the time of the buyout, but this could well be propaganda.
Market Data 
Markets 
AI
